List of Funded Biotech Startups (2025)
Biotech startups are advancing at record speed and these startups just raised the funding to push boundaries even further.
From gene therapies and precision medicine to diagnostic platforms and synthetic biology, recently funded biotech startups are tackling some of the world’s biggest healthcare challenges. Backed by fresh rounds of capital, they’re expanding research teams, accelerating clinical development, and partnering with vendors who can help them bring breakthroughs to market faster.
At Fundraise Insider, we track every biotech startup that secures new funding and deliver verified contact details for the scientists, founders, and innovation leaders driving them forward.
👉 Get 250+ Funded Startup Leads like biotech startups every week.
List of Funded Biotech Startups
Download the full list of funded startups + decision maker contacts
FAQs: Selling to Biotech Startups
1. What types of companies are considered biotech startups?
Biotech startups include companies working on drug discovery, genetic engineering, diagnostics, cell and gene therapy, biosensors, clinical trial platforms, and other biology driven innovation. They often operate at the intersection of research, technology, and medicine.
2. What is the typical focus of biotech startups after raising capital?
Recently funded biotech startups usually focus on scaling research and development, preparing for preclinical or clinical trials, securing regulatory approvals, expanding lab infrastructure, and building scientific or technical teams.
3. Who are the best contacts inside biotech startups for vendor outreach?
Depending on the service you offer, the right contacts may include:
- CEO or Co-founder
- Chief Scientific Officer or Head of Research
- COO or Lab Manager
- Regulatory Affairs Lead or Clinical Director
- Head of Product or Platform Engineering
4. What services are most relevant to early stage biotech companies?
Biotech startups often outsource:
- Laboratory software and digital infrastructure
- Clinical trial management platforms
- Regulatory consulting and documentation support
- Brand and website development for investors and partners
- Automation and analytics tools for lab workflows
5. How can I add value to a biotech company if I am not in the life sciences space?
Even if your offering is not life sciences specific, biotech startups still need support with HR systems, recruiting, IT security, finance tools, project management, and storytelling for investor updates or public visibility. Focus on how your service solves a key operational challenge.
6. What should I avoid when reaching out to a biotech startup?
Avoid using technical buzzwords loosely or generalizing scientific processes. These companies work in highly specialized domains. Instead, focus on your track record of working with complex or regulated businesses and how you can speed up time to milestone.
7. How do biotech startups make vendor decisions?
Vendor decisions are often made by a small executive team, and technical validation is critical. They prioritize credibility, regulatory awareness, ease of implementation, and peer references. Show how your solution has been used by other high trust or regulated environments.
8. What is the role of venture capital in shaping vendor choices?
Biotech startups backed by institutional investors are usually under pressure to show progress quickly. This means vendors who can help them meet timelines or prepare for the next fundraising round are in a strong position. Mentioning that you support investor backed teams can add credibility.
9. What kind of messaging works best when pitching to biotech founders?
Founders in biotech prefer precise, informed messaging. Avoid hype and get to the point. Share 1 to 2 sentences about what you do, how it directly helps their type of business, and offer something actionable like a relevant case study or fast discovery call.
10. How can I stay updated on biotech startups that raise new funding?
Subscribe to Fundraise Insider to get weekly updates on recently funded biotech startups. Each report includes company info, funding details, and direct contact data so you can reach decision makers at the right time.
Analyzing Funded BioTech Startups by Location
BioTech startups in San Diego (10 companies)
- Modulo Bio (Seed – 19 Mar 2025)
- Orphagen Pharmaceuticals (Grant – 9 Dec 2024)
- Aizen Therapeutic (Seed – 21 Nov 2024)
- Adaptilens (Series A – 29 Apr 2024)
- …and six more early-stage drug discovery and diagnostic innovators
BioTech startups in Cambridge, MA (8 companies)
- Be Biopharma (Series C – 15 Jan 2025)
- Labviva (Series B – 13 Jan 2025)
- AvenCell (Series B – 22 Oct 2024)
- Diagonal Therapeutics (Series A – 3 Apr 2024)
- …and three others at Series B or undisclosed venture rounds
BioTech startups in New York, NY (5 companies)
- Ataraxis (Series A – 5 Mar 2025)
- Formation Bio (Series D – 26 Jun 2024)
- Rumi Scientific (Grant – 3 Jun 2024)
- Volastra Therapeutics (Venture – 30 May 2024)
- …plus one more growth stage innovator
BioTech startups in Boston, MA (4 companies)
- Axonis Therapeutics (Series A – 30 Oct 2024)
- CytoTronics (Seed – 5 Sep 2024)
- Ayana Bio (Grant – 1 May 2024)
- Adaptilens (Series A – 29 Apr 2024)
BioTech startups in San Francisco, CA (3 companies)
- Trilobio (Seed – 6 May 2025)
- Indapta Therapeutics (Venture – 17 Dec 2024)
- Rubi Laboratories (Grant – 5 Dec 2024)
Key BioTech Startups Spotlight
-
Be Biopharma (Cambridge)
- Stage: Series C (15 Jan 2025)
- Focus: Gene editing therapeutics for rare diseases
- Why to watch: Their $40 M Series C round positions them for first-in-human studies in 2026.
-
Formation Bio (New York)
- Stage: Series D (26 Jun 2024)
- Focus: AI-driven biomanufacturing optimization
- Why to watch: The only Series D in the cohort, scaling from pilot to factory operations.
-
Axonis Therapeutics (Boston)
- Stage: Series A (30 Oct 2024)
- Focus: mRNA-based vaccine platforms
- Why to watch: Combines VC backing with NIH grants to pioneer novel adjuvant systems.
-
Orphagen Pharmaceuticals (San Diego)
- Stage: Grant-funded (9 Dec 2024)
- Focus: Rare-disease enzyme therapies
- Why to watch: SBIR grant underwrites their first-in-human trials.
-
Trilobio (San Francisco)
- Stage: Seed (6 May 2025)
- Focus: Single-cell proteomics analytics
- Why to watch: An $8 M seed led by AI specialist VC highlights surge in single cell omics.